ER niacin/laropiprant

DRUG2 trials

Sponsors

University of Oxford, Merck Sharp & Dohme LLC

Conditions

Cardiovascular DiseaseCoronary Heart DiseaseDiabetes MellitusDiabetes Mellitus Type 2Peripheral Arterial Disease

Phase 3

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

CompletedNCT00461630

University of OxfordCardiovascular Disease, Coronary Heart Disease, Diabetes Mellitus +1

Start: 2007-01-31End: 2012-10-31Updated: 2014-02-28

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

CompletedNCT00485758

Merck Sharp & Dohme LLCDiabetes Mellitus Type 2

Start: 2007-07-31End: 2008-08-31Updated: 2015-10-12

Related Papers

Investigating modifications to participant information materials to improve recruitment into a large randomized trial.

2019-12-056 citations

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

2019-08-2219 citations

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes

JAMA Network Open2019-03-0119 citations

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study

Circulation Genomic and Precision Medicine2018-02-0192 citations

Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs

Circulation Cardiovascular Quality and Outcomes2016-07-019 citations

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Vascular Health and Risk Management2015-02-019 citations

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

New England Journal of Medicine2014-07-111639 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.

2012-06-0114 citations

Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.

2012-03-0810 citations